Submit Deal

VERACYTE

Summary

Veracyte is a genomic diagnostics company. It provides genomic diagnostic products and services to improve patient care against diseases such as thyroid cancer, lung cancer, and idiopathic pulmonary fibrosis.

Deals Overview

Total Deals3

Valued Deals3

Total Value£ 738 M

Avg. Deal Size£ 246 M

Market Context

Senior Management

Bonnie Anderson
Chairman and CEO
Marc Stapley
CEO
Keith Kennedy
CFO

Sort

decipher biosciences

HQ - United States

Biotechnology

15 Mar 2021

Investment Date

100%

Stake

£ 439 M

Deal Value

haliodx

HQ - France

Biotechnology

3 Aug 2021

Investment Date

100%

Stake

£ 224 M

Deal Value

c2i genomics

HQ - United States

Biotechnology

6 Feb 2024

Investment Date

100%

Stake

£ 74 M

Deal Value

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy